← Back to Clinical Trials
Recruiting NCT02329652

NCT02329652 Multi-functional Neuroprosthetic System for Restoration of Motor Function in Spinal Cord Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02329652
Status Recruiting
Phase
Sponsor Anne Bryden
Condition Spinal Cord Injuries
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2014-12-01
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 17 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Networked Neuroprosthetic System for Grasp and Trunk

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2014-12-01 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is to evaluate the use of a fully implanted device for providing hand function, reach, and trunk function to individuals with cervical spinal cord injury. Funding Sources: FDA OOPD NIH NINDS

Eligibility Criteria

Inclusion Criteria: * Diagnosis of cervical level spinal cord injury, either complete or incomplete; International Standards for Neurological Classification of Spinal Cord Injury (INCSCI) motor level of C4 through C8; American Spinal Injury Impairment Scale (AIS) grade A, B, C, or D; six months or more post-injury * Biceps/brachialis/brachioradialis strength of 2/5 or higher on Manual Muscle Test * Peripheral nerve innervation to upper extremity and trunk muscles, including a grade 3/5 or higher stimulated strength (Manual Muscle Test) in at least two of the following muscles in one arm: adductor pollicis, abductor pollicis brevis, flexor pollicis longus, extensor pollicis longus, extensor digitorum communis, flexor digitorum superficialis, flexor digitorum profundus, pronator quadratus, extensor carpi ulnaris, extensor carpi radialis brevis, extensor radialis longus, flexor carpi ulnaris, flexor carpi radialis, first dorsal interosseous; and in at least two of the following muscles: left/right gluteus maximus, left/right erector spinae, left/right quadratus lumborum, * Age \> 16 years * Medically stable - cleared for surgery * Able and willing to take part in study Exclusion Criteria: * Currently pregnant (neuroprosthesis implantation delayed until no longer pregnant) * Other neurological conditions (multiple sclerosis, diabetes with peripheral nerve involvement) * History of coagulopathy, HIV, severe cardiopulmonary disease, severe bradycardia, severe autonomic dysreflexia, or chronic obstructive pulmonary disease. * Active untreated infection such as decubitus ulcer, urinary tract infection, pneumonia * Presence of other active implantable medical devices with unknown or untested interaction with the NNP implant * Active implantable medical device (AIMD) such as a pacemaker or defibrillator, with the exception of the implanted stimulator-telemeter (IST) or implanted receiver stimulator (IRS) systems developed by the Cleveland Functional Electrical Stimulation Center * Unhealed fractures that prevent functional use of arm or trunk * Less than six months post-injury (neuroprosthesis implantation delayed until criteria met) * Extensive upper extremity denervation (fewer than two stimulatable hand muscles and two stimulatable trunk muscles) * Involvement in other ongoing clinical studies that exclude concurrent until criteria met) * Disorder or condition that require MRI monitoring * Mechanical ventilator dependency * Progressive SCI In subjects who are undergoing bilateral implantation, subjects should not have a history of autonomic dysreflexia, hypertension, diabetes or any condition which requires frequent blood pressure monitoring or frequent venipuncture. * Adverse interaction between system components and typical electromagnetic (EM) sources in subject's home and work environments, including wheelchair or other active implantable devices.

Frequently Asked Questions

Who can join the NCT02329652 clinical trial?

This trial is open to participants of all sexes, aged 17 Years or older, studying Spinal Cord Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02329652 currently recruiting?

Yes, NCT02329652 is actively recruiting participants. Visit ClinicalTrials.gov or contact Anne Bryden to inquire about joining.

Where is the NCT02329652 trial being conducted?

This trial is being conducted at Cleveland, United States.

Who is sponsoring the NCT02329652 clinical trial?

NCT02329652 is sponsored by Anne Bryden. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology